{"id":"W2919228285","doi":"10.1080/13696998.2019.1590842","title":"Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Western University; University of Alberta; William Osler Health System; Roche (Canada)","funders":"","keywords":"Atezolizumab; Docetaxel; Medicine; Nivolumab; Oncology; Lung cancer; Cost effectiveness; Clinical trial; Internal medicine; Chemotherapy; Cancer; Immunotherapy; Risk analysis (engineering)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002177313,0.001072636,0.001148811,0.001062947,0.0008562522,0.002067655,0.001531891,0.001094838,0.003429803],"category_scores_gemma":[0.01093547,0.0005029028,0.002565692,0.001328229,0.0006836337,0.0008252933,0.0008997036,0.001595056,0.0001245937],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.07832159,"about_ca_system_score_gemma":0.07159378,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9517595,"about_ca_topic_score_gemma":0.9442334,"domain_scores_codex":[0.998714,0.0004669532,0.00005652142,0.0001424403,0.0003085466,0.0003114593],"domain_scores_gemma":[0.9973645,0.001076278,0.0003560601,0.0000552258,0.0007470879,0.0004007985],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01565409,0.0008751741,0.06323203,0.003547428,0.005406884,0.0006344479,0.0002058286,0.7645606,0.001096262,0.01379303,0.01471277,0.1162815],"study_design_scores_gemma":[0.008114524,0.003958237,0.1034946,0.002090672,0.01104419,0.0008393644,0.0008832753,0.8355688,0.002189635,0.009417695,0.02207609,0.0003229605],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.899478,0.04172386,0.007631793,0.01061679,0.000349918,0.001487835,0.02050716,0.0001788578,0.0180259],"genre_scores_gemma":[0.9908423,0.003418709,0.00184532,0.0003638677,0.00002032497,0.0001137386,0.002082325,0.00001572456,0.001297681],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9216784,"threshold_uncertainty_score":0.5682656,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01627561786555592,"score_gpt":0.2918249683696434,"score_spread":0.2755493505040875,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}